RiLuzole pill to reduce atrial fibrillation on heart monitoring
Treatments studied
Part of Heart & circulation clinical trials.
This Phase 2 study tests whether riLuzole can reduce episodes of atrial fibrillation (an irregular heart rhythm) around the time of planned cardioversion. Doctors will monitor your heart using a Holter monitor to count and compare rhythm episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have had symptoms of atrial fibrillation (AF) that were confirmed on an EKG within the last 48 hours to 12 months
- You are planning to have cardioversion (a procedure to reset heart rhythm) and will be taking blood thinners (or are already on them for cardioversion)
- You are not currently taking an anti-arrhythmia medicine (a drug meant to control abnormal heart rhythms) as part of your usual care
- Your blood pressure is not very high (top number must be 180 or less, bottom number must be 100 or less)
- You have no “temporary” cause of AF such as major electrolyte imbalance, hyperthyroidism, or pericarditis (heart lining inflammation)
- You agree to the study and can follow requirements (including heart monitoring) and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses two types of energy (pulsed field and radiofrequency) to fix the heart's electrical signals in people with paroxysmal atrial fibrillation (AFib that comes and goes). It aims to be more effective and safer than standard ablation alone.
This trial uses a home heart monitor (a chest patch with an ECG) to study how atrial fibrillation (an irregular heartbeat) changes over time and how this may help manage symptoms. You may be included if you have a documented, short-lasting type of atrial fibrillation and a moderate amount of AF seen on a 14-day heart recording.
This study tests a stepwise treatment plan for people with persistent atrial fibrillation (a long-lasting irregular heartbeat) who also have an enlarged left atrium. It aims to see if a medication called amiodarone plus a cardioversion procedure can help restore normal rhythm.
This trial tests whether chloroquine can reduce symptoms in people with persistent atrial fibrillation (AF), an irregular heartbeat that lasts longer than a week. It will also closely monitor heart rhythm and safety, since the medicine can affect the heart and other organs.
This study tests a new drug called BAY 3670549 to see if it can help convert atrial fibrillation (an irregular heartbeat) back to normal rhythm. You'll receive the study drug or a placebo along with a procedure to restore your heart's normal rhythm, and researchers will monitor how well it works and how safe it is.
This trial studies abnormal electrical signals in the right upper heart chamber and how they relate to atrial fibrillation (AF). It may help improve how doctors target AF treatment during catheter ablation for people who have AF symptoms.
Hear when a new Atrial Fibrillation Paroxysmal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.